statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET In accordance with article 15 of the Law...

Information on the total number of voting rights and shares

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology Head & Neck Surgery FoundationFirst medical device company to become a corporate champion...

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology   Head & Neck Surgery Foundation

HC Wainwright reaffirmed their buy rating on shares of Nyxoah (NASDAQ:NYXH  Free Report) in a research note published on Wednesday, Benzinga reports. The firm currently has a $22.00 price...

Nyxoah (NASDAQ:NYXH) Stock Rating Reaffirmed by HC Wainwright

Nyxoah (NASDAQ:NYXH  Free Report) had its target price hoisted by Stifel Nicolaus from $20.00 to $27.00 in a report issued on Wednesday, Benzinga reports. Stifel Nicolaus currently has a buy...

Nyxoah (NASDAQ:NYXH) PT Raised to $27.00 at Stifel Nicolaus

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Nyxoah price target raised by $7 at Stifel, here's why

Nyxoah price target raised by $4 at H.C. Wainwright, here's why

Nyxoah says Genio pivotal study meets primary endpoints...

Nyxoah says Genio pivotal study meets primary endpoints

Nyxoah announces DREAM study meets primary endpoints

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen...

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

HC Wainwright reissued their buy rating on shares of Nyxoah (NASDAQ:NYXH  Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $18.00 target...

HC Wainwright Reiterates Buy Rating for Nyxoah (NASDAQ:NYXH)

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Volume	22,041.00
52-Wk High	$20.00
52-Wk Low	$4.00

NYXH Nyxoah SA

About

Feed

News

Earnings

Fundamentals